Orforglipron – Wholesale & Bulk Supply (Research Use Only)
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist in late-stage clinical development. Ideal for obesity and type 2 diabetes research programs seeking an oral small-molecule alternative to injectables.
B2B supply for CROs, universities, and pharmaceutical developers • Global shipping • COA on request
Key Highlights
- Small-Molecule, Oral: Once-daily tablet format; no cold chain required—streamlines logistics and scale-up studies.
- GLP-1 Agonist: Targets GLP-1 receptor; supports weight-management and glycemic-control research endpoints.
- Late-Stage Development: Ongoing Phase III programs in obesity and type 2 diabetes research contexts.
Product Overview
Orforglipron (LY3502970) is a first-in-class oral GLP-1 receptor agonist developed for once-daily dosing. Unlike peptide GLP-1s (e.g., semaglutide, tirzepatide), orforglipron’s small-molecule design supports oral administration and simplified handling. It is currently an investigational compound and is available strictly for laboratory research use only.
Technical Specifications
| Compound | Orforglipron (LY3502970) |
|---|---|
| Type | Non-peptide GLP-1 receptor agonist |
| Form | Oral small molecule (tablet / powder for R&D workflows) |
| Status | Investigational (Research Use Only; not for human consumption) |
| Applications | Obesity pharmacotherapy research; Type 2 diabetes R&D; metabolic studies |
| Documentation | COA on request; batch traceability available |
| MOQ | Flexible (inquire for pilot vs scale) |
| Packaging | Research-grade bulk packaging; tamper-evident seals |
Scientific Summary
- Weight-management outcomes: Late-stage studies report double-digit mean weight reduction at higher doses in non-diabetic cohorts.
- Glycemic control: HbA1c reductions reported in type 2 diabetes research populations.
- Tolerability: Predominantly GI-related AEs typical of GLP-1 class (nausea, diarrhea, constipation) in trials.
- Operational advantages: Oral dosing removes cold-chain constraints, aiding multi-site or decentralized designs.
Note: Orforglipron remains investigational. All statements pertain to research contexts and public trial data. No claims of safety or efficacy are made for clinical or consumer use.
Orforglipron vs Other GLP-1 Pathway Agents
| Compound | Form | Mechanism | Typical Weight-Loss (Research) | Status |
|---|---|---|---|---|
| Orforglipron | Oral (daily) | GLP-1 agonist | ~Double-digit mean reduction at higher doses* | Phase III |
| Semaglutide | Weekly injection | GLP-1 agonist | ~15–17% (dose-dependent) | Approved |
| Tirzepatide | Weekly injection | GLP-1 + GIP dual agonist | ~20%+ | Approved |
| Retatrutide | Weekly injection | GLP-1 + GIP + Glucagon (triple) | ~24%+ (Phase II data) | Phase II/III |
*Aggregated from publicly reported trial readouts; not directly comparable across studies.
See also: Semaglutide Wholesale • Tirzepatide Wholesale • Retatrutide (Research)
Wholesale & Logistics
Supply Options
- Pilot and scale quantities for R&D environments
- Global shipping with compliant paperwork
- Batch COA and QC documentation
- Secure, serialized packaging
Buyer Eligibility
- CROs, universities, pharma R&D groups
- Qualified B2B distributors and labs
- Not sold to consumers; not for clinical use
Safety & Legal Notice
Orforglipron is an investigational research compound. Not for human consumption, medical treatment, or clinical use. Purchases are restricted to qualified institutional or professional buyers.
Request a Quote
Tell us your target quantity, delivery location, and documentation needs. Our B2B team will respond within one business day.
Prefer direct? Whatsapp +44 7880 485232 or email info@sarmsdirect.com.
Orforglipron – Frequently Asked Questions
Is orforglipron available for consumer use?
No. It is an investigational compound for research use only.
Do you supply COAs?
Yes. Batch COAs and QC documentation are available on request for qualified buyers.
What are typical research endpoints?
Weight-management and glycemic-control outcomes (e.g., body-weight change, HbA1c, metabolic markers), per protocol.
Can you white-label or support formulation work?
Yes, for eligible B2B partners we can discuss white-label and formulation support for R&D contexts.
